Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Modeling an anti-amyloid combination therapy for Alzheimer's disease.

Science translational medicine - 6 Jan 2010

Chow Vivian W, Savonenko Alena V, Melnikova Tatiana, Kim Hyunsu, Price Donald L, Li Tong, Wong Philip C

Abstract excerpt

As only symptomatic treatments are now available for Alzheimer's disease (AD), safe and effective mechanism-based therapies remain a great unmet need for patients with this neurodegenerative disease. Although gamma-secretase and BACE1 [beta-site beta-amyloid (Abeta) precursor protein (APP) cleaving enzyme 1] are well-recognized therapeutic targets for AD, untoward side effects associated with strong inhibition or...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alzheimer Disease
Share to Amyloid
Share to Amyloid Precursor Protein Secretases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aspartic Acid Endopeptidases

Share to Behavior, Animal

Share to Combined Modality Therapy

Share to Maze Learning

Share to Models, Animal

Source

Open in PubMed Open full text

Identifiers

PMID: 20371462
DOI: 10.1126/scitranslmed.3000337
PMCID: PMC2852193

Genes

BACE1
APP

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Modeling an anti-amyloid combination therapy for Alzheimer's disease.PMID 20371462Read ↗

Modeling Alzheimer’s disease: from past to futureSemantic proximity Read ↗

Presenilin-1 but not amyloid precursor protein mutations present in mouse models of Alzheimer's disease attenuate the response of cultured cells to γ-secretase modulators regardless of their potency and structure.Semantic proximity Read ↗

Moderate reduction of gamma-secretase attenuates amyloid burden and limits mechanism-based liabilities.Semantic proximity Read ↗

BACE1 (β-secretase) inhibitors for the treatment of Alzheimer's diseaseSemantic proximity Read ↗

A novel BACE inhibitor NB-360 shows a superior pharmacological profile and robust reduction of amyloid-β and neuroinflammation in APP transgenic mice.Semantic proximity Read ↗

Natural compounds that modulate BACE1-processing of amyloid-beta precursor protein in Alzheimer's disease.Semantic proximity Read ↗

Beneficial effects of the β-secretase inhibitor GRL-8234 in 5XFAD Alzheimer's transgenic mice lessen during disease progression.Semantic proximity Read ↗

{gamma}-Secretase Substrate Concentration Modulates the Abeta42/Abeta40 Ratio: IMPLICATIONS FOR ALZHEIMER DISEASE.Semantic proximity Read ↗

Characterization of FRM-36143 as a new γ-secretase modulator for the potential treatment of familial Alzheimer's disease.Semantic proximity Read ↗

The role of amyloid precursor protein processing by BACE1, the beta-secretase, in Alzheimer disease pathophysiology.Semantic proximity Read ↗

Closing in on the amyloid cascade: recent insights into the cell biology of Alzheimer's disease.Semantic proximity Read ↗

beta-Secretase inhibitor potency is decreased by aberrant beta-cleavage location of the "Swedish mutant" amyloid precursor protein.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.